When was Breezebio founded?

Breezebio was founded in 2021 and raised its 1st funding round within a year of its incorporation.

Where is Breezebio located?

Breezebio is headquartered in San Francisco, United States.

How many employees does Breezebio have?

As of Oct 31, 2026, the latest employee count at Breezebio is 64.

Is Breezebio a funded company?

Breezebio is a funded company, having raised a total of $110M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 23, 2021.

When was the latest funding round of Breezebio?

Breezebio's latest funding was a $***** Series B round on Feb 25, 2026, with participation from 13 investors.

Where does Breezebio rank among its competitors?

Breezebio ranks 132nd amongst 905 active competitors, of which 327 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Breezebio?

Breezebio's top competitors include Sana Biotechnology, Abcellera Biologics and Agios Pharmaceuticals. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Breezebio - 2026 Company Profile, Team, Funding & Competitors

Breezebio is a series B company based in San Francisco (United States), founded in 2021 by Hyo Min Park. It operates as a Developer of programmable nanoparticle delivery platforms for genetic medicine therapies. Breezebio has raised $110M in funding from DSC Investment and Yuanta Investment. The company has 905 active competitors, including 327 funded and 187 that have exited. Its top competitors include companies like Sana Biotechnology, Abcellera Biologics and Agios Pharmaceuticals.

Company Details

Developer of programmable nanoparticle delivery platforms for genetic medicine therapies. This technology enables the transport of genetic payloads to specific cells and tissues to regulate biological processes. The delivery vehicles are designed to be non-immunogenic to avoid triggering immune responses during treatment. These therapies focus on modulating immune system activity to address autoimmune conditions and other diseases. The approach aims to restore immune balance by targeting specific cells while leaving the remainder of the immune system functional.

Key Metrics

Founded Year

2021

Location

San Francisco, United States

Stage

Series B

Total Funding

$110M in 3 rounds

Latest Funding Round

Series B, Feb 25, 2026, $*****

Investors

DSC Investment & 30 more

Ranked

132^nd among 905 active competitors

Employee Count

64 as on Oct 31, 2026

Similar Companies

Sana Biotechnology & 1092 more

View Breezebio's full profile

Breezebio has raised a total funding of $110M over 3 rounds. Its first funding round was on Sep 23, 2021. Its latest funding round was a Series B round on Feb 25, 2026 for $*****. 13 investors participated in its latest round. Breezebio has 30 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Breezebio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 25, 2026	7117918	Series B	8716465	1694909	5263297	2171677
Jan 17, 2024	5696967	Series A	4180345	7035037	1408518	Sequoia Capital & 16 more
Sep 23, 2021	9127423	Series A	4236979	7882716	2343001	Eli Lilly & 11 more

Access funding benchmarks and valuations. Sign up today!

View details of Breezebio's funding rounds and investors

The founders of Breezebio is Hyo Min Park.

Here are the details of Breezebio's key team members:

Hyo Min Park: Co-Founder & COO of Breezebio.

View details of Breezebio's Founder profiles and Board Members

Breezebio's employee count trend

Breezebio has 64 employees as of Oct 26. Here is Breezebio's employee count trend over the years:

Uncover Breezebio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Breezebio include Sana Biotechnology, Abcellera Biologics and Agios Pharmaceuticals. Here is the list of Top 10 competitors of Breezebio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
2nd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
3rd	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
4th	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100
5th	Viridian Therapeutics 2007, Boulder (United States), Public	Developer of medicines for patients with serious and rare diseases	$14.5M	Longitude Capital, Fairmount Funds Management ... & 2 others	69/100
6th	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
7th	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Walvax & 16 others	67/100
8th	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates & 16 others	67/100
9th	Beijing Jiakesi drug development 2015, Beijing (China), Public	Developer of small molecule based therapeutics for cancer treatment	$55M	Qiming Venture Partners, Lilly Asia Ventures ... & 3 others	67/100
10th	Carmot 2008, Berkeley (United States), Acquired	Developer of disease-modifying therapies to treat metabolic diseases	$386M	The Column Group, Deep Track Capital & 17 others	66/100
132nd	Breezebio 2021, San Francisco (United States), Series B	Developer of programmable nanoparticle delivery platforms for genetic medicine therapies	$110M	SK, DCVC & 29 others	53/100